
Warm nights and ill premature babies?
A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium will take place on 3 - 4 September.

A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE researchers investigate gene activity in host cells

Diverse Origins – One Goal
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Janshoff S, Plümers R, Kohl A, Nocke M, Behrendt P, Knabbe C, Costa R, Vollmer T, Todt D, Steinmann E, Gömer A
Vandenabeele L, Ayanwale A, Pietschmann T, Nilsson-Payant B
Dinkelborg K, Niehaus C, Bremer B, Wundes C, Tiede A, Petruch N, Deterding K, Kraft A, Hartleben B, Cornberg M, Wedemeyer H, Behrendt P, Maasoumy B
Immunomodulatory drugs for rheumatic diseases specifically influence immune cells and messenger substances. This project investigates their effect on immune responses in order to find individually suitable therapies.
In collaboration with the Department of Neurology and the Metabolomics Department, the project is investigating metabolic products in cerebrospinal fluid in order to identify biomarkers for CNS infections and cell damage and to distinguish long COVID and viral from autoimmune diseases.
Together with the Department of Structural Biology at the University of Lübeck, human, strongly neutralizing antibodies against HEV were identified and characterized for the first time. These showed a protective effect in the mouse model and are currently being further developed for clinical application, including mRNA-based application methods.
Studies in the cell culture model show that only a few disinfectants are effective against HEV, which provides important information on hygiene measures for HEV infections. We are also working together to test vaccines for pigs as HEV reservoirs.

